

BCUK Background Briefing | Vitamin D & Breast Cancer

Introduction

Breast cancer is the most common cancer in women globally [1]. In the UK there are around 55,500 new cases of breast cancer in women and 370 in men, every year [2]. A person's risk of developing breast cancer depends on many factors, including those associated with age, hormones (in particular oestrogen), genetics, diet, lifestyle and the environment [3]. In 1990, scientists first reported an inverse association between total average annual sunlight and breast cancer mortality [4]. Since then, numerous studies have examined whether low levels of circulating vitamin D increase breast cancer risk and breast cancer mortality. In this brief, we evaluate recent studies on this topic. We also discuss how the body synthesises vitamin D and its mode of action and explain why it is difficult to establish whether or not taking vitamin D supplements is protective against breast cancer.

What is vitamin D and where does it come from?

Vitamins are essential organic compounds needed in small amounts for normal bodily function. Most cannot be made by the body and are obtained from the diet [5]. Vitamin D is an exception as it can be synthesised by the body provided there is sufficient exposure to sunlight, making intake from food unnecessary [6].

Vitamin D refers to a group of fat-soluble secosteroids (open ring steroids) [7] synthesised in skin cells in humans and some animals. It is naturally present in some foods, added to others (see Table 1) and may be taken as a dietary supplement [8].

Vitamin D production in the skin is the primary natural source of vitamin D. Synthesis is triggered when the sun's ultraviolet (UV) rays interact with skin [9]. According to [Yale Medicine](#), vitamin D derived from sunlight is functionally the same as that obtained from supplements; both can provide healthy vitamin D levels [10]. There is some

SUMMARY

Most studies have found low levels of circulating vitamin D are linked to an increased breast cancer risk. The body produces adequate levels of vitamin D if skin is exposed to sufficient sunlight. Other sources include diet or supplements. Studies have not demonstrated that taking vitamin D supplements reduces breast cancer risk, although taking these can restore serum vitamin D levels to a healthy state and are recommended for those unable to achieve sufficiency through sunshine and diet. The main function of vitamin D is maintaining extracellular calcium levels. It may help prevent breast cancer through its actions on cellular differentiation, breast cell growth, programmed cell death, reduction of cancer cell growth and tumour blood vessel formation and its effects on oestrogen pathways.

evidence that the vitamin D you synthesise from sunlight stays active in your body longer than the vitamin D obtained from supplements [11]. Furthermore, it is not possible to produce toxic levels of vitamin D from sunlight, whereas it is possible from supplements [12].

Table 1: Vitamin D content of selected foods [13]

Food	Vitamin D (µg/100g)
<i>Foods</i>	7.8 – 25.0
Naturally occurring Herring	16.0
Salmon	5.6
Egg yolk	4.0
Mackerel	2.9
Egg, whole Margarine	2.5 – 7.5
Chanterelle mushroom	2.1
Button mushroom Liver,	1.9
beef	1.7

BCUK Background Briefing | Vitamin D & Breast Cancer

Gouda cheese, 45% fat (dry matter)	1.3
Butter	1.2
Calf's liver	0.3
Whole milk, 3.5% fat	0.1
Fortified	
Multivitamin Whole Fresh Milk	2.2
Wholegrain oats (Ready Brek)	4.3
Almond milk	0.8
Soy milk	0.8

In foods and dietary supplements, vitamin D has two main forms, D₂ (ergocalciferol) and D₃ (cholecalciferol), that differ chemically only in their side-chain structures (Figure 1). Vitamin D₂ is present only in fungi (e.g., wild mushrooms or UVB-treated cultivated mushrooms, and UVB-treated yeasts), while D₃ comes mainly from animal sources. Some foods like milk and cereal are vitamin D₂- and D₃-fortified, while most vitamin D supplements contain vitamin D₃. As vitamin D is fat-soluble it is better absorbed if eaten with fat [8].




Figure 1: Structures of vitamin D₂ (ergocalciferol, from fungi) and vitamin D₃ (cholecalciferol, made by animals or given sunlight), showing vitamin D₂ has an additional methyl group (CH₃) (see arrows) [14].

Vitamin D synthesis and function

After vitamin D is synthesised in the skin upon exposure to UV light or acquired from food or supplements, it is stored in the body's fat cells. Here it remains inactive until it's needed. Through a process called hydroxylation, it is converted in the liver and kidney to the metabolically active form, 1,25-Dihydroxyvitamin D₃, commonly known as calcitriol (Figure 2). Synthesis begins when 7-dehydrocholesterol (provitamin D₃), derived from cholesterol in the liver and found in the skin, is broken down to previtamin D₃ upon exposure to UV-B light. Previtamin D₃ is then converted to vitamin D₃, transported to the blood by vitamin D binding protein and subsequently to the liver, wherein it is hydroxylated to 25-hydroxyvitamin D₃ (25(OH)D₃). This is the major circulating metabolite and the storage form of vitamin D, mainly located in the skin, liver, skeletal muscle and fat tissue [15]. Similarly, dietary vitamin D₂ or vitamin D₃ are converted to 25(OH)D₃ in the liver. Vitamin D status is normally based on serum levels of 25(OH)D₃. To be biologically active, 25(OH)D₃ needs to be converted to 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃), which occurs in the kidney [16] (see also table 2).

1,25(OH)₂D₃ acts as a steroid hormone [17] which exerts its action by binding to an intracellular nuclear receptor, the vitamin D receptor (VDR). This receptor, first identified in a breast cancer cell line in 1979, regulates gene expression by acting as a transcription factor (DNA-binding protein involved in transcribing DNA into RNA). In addition to its main function of maintaining extracellular calcium levels, activation of VDR influences up to 200 genes that mediate cellular growth, differentiation and apoptosis (programmed cell death) [18].

BCUK Background Briefing | Vitamin D & Breast Cancer




Figure 2: Vitamin D synthesis. Vitamin D can be synthesized in the skin (vitamin D₃) or provided in the diet (vitamin D₂ or D₃). It is converted by reactions occurring first in the liver (making 25-Hydroxyvitamin D₃) and then kidney (making 1,25-Dihydroxyvitamin D₃, the active form) [19].

Table 2: Nomenclature of Vitamin D

Vitamin D	Synonyms	Abbreviation	Comments
Provitamin D3	7-Dehydrocholesterol	DHC	Photochemically converted to vitamin D3 in the skin
Vitamin D3	Cholecalciferol	-	Synthesised in skin when exposed to sunlight Found in foods of animal origin (e.g. oily fish), fortified foods and dietary supplements
Vitamin D2	Ergocalciferol	-	Found in mushrooms (grown in UV light), fortified foods and dietary supplements
25-Hydroxyvitamin D	Calcidiol/Calcifediol	25(OH)D ₃	Best reflects vitamin D status
1,25-Dihydroxyvitamin D	Calcitriol	1,25-(OH) ₂ D ₃	Active form of vitamin D

Vitamin D has several functions in the body. It promotes calcium absorption in the gut, maintains adequate serum calcium and phosphate concentrations to enable normal bone mineralisation and is needed for bone growth. Without sufficient vitamin D bones can become thin. Together with calcium, vitamin D helps protect older adults from osteoporosis. Vitamin D reduces inflammation and modulates processes such as cell growth, neuromuscular and immune function and glucose metabolism. Many genes encoding proteins that regulate cell proliferation, differentiation and apoptosis are modulated in part by vitamin D [20]. Vitamin D has been investigated for its potential role in reducing the risk of many diseases, including cardiovascular disease and cancer, including breast cancer [21].

What is a healthy level of vitamin D?

Your vitamin D level depends on many factors such as how much time you spend outdoors, what you eat, what medications you take, but also on your age

BCUK Background Briefing | Vitamin D & Breast Cancer

and skin type [20]. Most people in the northern hemisphere can make enough vitamin D from daily sun exposure with their forearms, hands or lower legs uncovered (without¹ sunscreen) from late March to the end of September (e.g. Caucasians across the UK need 10-15 minutes; for darker skin types, 25-40 minutes is recommended [22]). The vitamin D is stored by the body and helps maintain adequate levels in winter. Diet, for example liver, eggs or oily fish - such as salmon or herring, can provide small amounts of vitamin D [9].

According to the NHS, serum 25(OH)D₃ levels of >50 nmol/L² are adequate and sufficient for bone health in most people [23].

Vitamin D deficiency and use of supplements

If you are healthy and regularly spend time outdoors, you are unlikely to be vitamin D deficient. However, due to limited sunlight, especially during winter months, this deficiency is common in the UK population; with 19% children aged 11-18 years, 16% adults aged 19-64 years and 13% adults aged 65 years and over (although higher in institutionalised older people) considered vitamin D deficient [24]. Vitamin D deficiency in infants can lead to rickets, which causes bone deformities, although this condition is rare in the UK. In adults, deficiency can result in osteomalacia, a condition causing bone pain, and in older adults, osteoporosis [25]. Vitamin D supplements are used to prevent and treat these conditions.

To detect vitamin D deficiency, a laboratory blood test is necessary. The NHS defines a deficiency as circulating levels of 25(OH)D₃ below 25 nmol/L [23]. Other countries define

¹ Prolonged exposure to sunlight can cause sunburn and may lead to skin cancer.

differently, for example Germany, which considers levels below 30 nmol/l as deficient [26].

Who is most at risk of vitamin D deficiency?

Those at higher risk of vitamin D deficiency include:

- people around 65 years of age or older; the skin's ability to produce vitamin D often decreases with age
- people who rarely get outside, due to illness, the need for care or other reasons
- babies who need to be protected from direct sunlight in the first year of life
- women who cover their bodies when outside their homes for cultural or religious reasons
- people with coloured skin who cannot produce enough vitamin D due to insufficient exposure to sunlight, for example those who reside in northern Europe
- people with certain diseases, for example, intestinal diseases which impair absorption of vitamin D (from dietary sources) [27].
- people carrying variants of certain genes involved in the metabolism, catabolism, transport, or binding of vitamin D to its receptor, which result in low vitamin D levels [28].

How much vitamin D should be taken as supplements?

A daily supplement containing 10 µg of vitamin D (400 IU)³ is recommended by the NHS (see [here](#) for details) [9].

Vitamin D toxicity

While you can't get too much vitamin D through sunshine you can through supplements, which can lead to health problems such as hypercalcaemia, where excess calcium builds up in the body. This can

² Serum concentrations of 25(OH)D₃ are reported in both nanomoles per litre (nmol/l) and nanograms per millilitre (ng/ml). One nmol/l = 0.4 ng/ml & 1 ng/ml = 2.5 nmol/l.

³ The amount of vitamin D can be expressed as International Units (IU), where 1 µg of vitamin D is equal to 40 IU.[29].

BCUK Background Briefing | Vitamin D & Breast Cancer

lead to weakened bones and damage kidneys and the heart [12]. Ingesting more than 4000 IU per day (100 µg/day) increases the risk of harmful health effects, for example kidney damage. Serum 25(OH)D₃ levels of more than 125 nmol/l are linked to adverse effects, especially if levels exceed 150 nmol/l [8].

Association between low vitamin D levels and an increased breast cancer risk⁴

Most studies have found low serum vitamin D is associated with increased breast cancer risk.

Observational studies

Observational studies are those which investigate the rate of an outcome in groups that were differently exposed to a risk factor. They are used to assess associations but the potential for biases means that these associations might not be causal. [30]. However, all of the studies discussed here included adjustment for the following confounders (in simple words: something, other than the thing being studied, that could be causing the results seen in a study), among others: race/ethnicity, education, hormonal birth control use, hormone therapy use, menopausal status, physical activity, BMI, alcohol consumption, parity and BMI.

Of the observational studies which were conducted in the chosen time period⁴, two found that a vitamin D deficiency was associated with an increased risk of breast cancer [31, 32], one found high serum vitamin D levels were associated with a lower risk of getting breast cancer [33], while one found no association [34].

Three reviews and meta-analyses, combining the results of several observational studies, concluded that a 25(OH)D₃ deficiency was linked to an increased breast cancer risk [17, 35, 36], and three suggested a protective relationship between high

circulating vitamin D and breast cancer [37–39]. Although one 2014 meta-analysis found that healthy vitamin D status was only weakly associated with low breast cancer risk, breast cancer survival showed a strong association [40]. A 2018 analysis of two randomised controlled trials and one observational study (see below for descriptions of different types of studies) concluded that women with serum levels of 25(OH)D₃ above 150 nmol/l, (although considered toxic), had one-fifth of the risk of breast cancer compared to those with less than 50 nmol/l [38]. It is important to mention that some meta-analyses show between-study heterogeneity [41] (variation between studies is referred to as heterogeneity; studies in a systematic review usually vary among themselves due to different populations, interventions or measurement methods). Large systematic differences between studies limit the trustworthiness of the pooled overall result.

Mendelian randomisation studies

In contrast to the above findings, one large Mendelian randomisation study found no causal effect of circulating 25(OH)D₃ on breast cancer risk [42]. Mendelian randomisation is a research method that provides evidence about causal relations between modifiable risk factors and disease, using genetic variants. This study took advantage of the fact that some people are born with gene variations that predispose them to low vitamin D levels. A Mendelian randomisation study is less likely to be affected by confounding factors (those that make it difficult to isolate the effect of the intervention) than other types of observational studies.

Observational studies of breast cancer and vitamin D have shown inverse associations between increased sunlight exposure and reduced breast

⁴ We looked at studies from the years 2010–2021.

BCUK Background Briefing | Vitamin D & Breast Cancer

cancer incidence as well as breast cancer mortality [4, 43–47].

In summary, most observational studies suggest that healthy vitamin D levels are protective against breast cancer risk, however one large study, the mendelian randomisation study, did not provide evidence for this.

How could vitamin D protect against breast cancer? Vitamin D may affect breast cancer development through several mechanisms of action, which are summarised in Figure 3.

Vitamin D is converted to $1,25(\text{OH})_2\text{D}_3$ in several different tissues, including breast tissue (Figure 2). $1,25(\text{OH})_2\text{D}_3$, in turn, binds to VDR, which regulates many genes, some of which are linked to cancer, including the oncogene *ID1*. An oncogene is a gene that has the potential to cause cancer if mutated or overexpressed. Overexpression of *ID1* is associated with mammary tumour growth and metastasis [48].

In studies of breast cancer cells grown *in vitro* and of tumours in mice, vitamin D has been found to slow or prevent the development of breast cancer by promoting cellular differentiation (a process in which healthy cells become specialised so that they can carry out their function in the body), cancer cells often reproduce very quickly and don't fully differentiate); controlling normal breast cell growth, decreasing cancer cell growth; stimulating apoptosis and reducing tumour blood vessel formation (angiogenesis). It also exhibits anti-inflammatory effects and decreases the expression of aromatase, an enzyme responsible for oestrogen synthesis. Oestrogens increase the risk of developing breast cancer, mainly because of their ability to increase rates of cell division and promote growth of oestrogen-responsive tumours. Vitamin D also downregulates oestrogen receptor (ER)-alpha, a

nuclear receptor that mediates the actions

⁵ We looked at studies from the years 2010–2021.

of oestrogen. In addition, VDR knockout mice (genetically modified mice carrying an inactivated VDR gene) exhibit enhanced cancer development [49]. Other important functions of vitamin D include suppression of metastasis (cancer spread) [50] and regulation of the immune system [51, 52].




Figure 3: Summary of the mechanisms of action of vitamin D in breast cancer.

Epidemiological studies⁵ that examine whether vitamin D supplements reduce breast cancer risk *Randomised controlled trials and meta-studies* Large randomised controlled trials (RCTs) are the reference standard for studying causal relationships between interventions and outcomes (i.e. if one event causes another event to occur) as they eliminate much of the bias within other study designs [53]. Most randomised RCTs do not support a protective effect of vitamin D supplements [54–57].

Of the five RCTs we looked at, four found no association between vitamin D supplementation and a reduced breast cancer risk [54–57]. Two RCTs found a reduced risk for *in situ* ductal carcinoma of the breast (a non-invasive breast cancer) [58] and vitamin D supplementation [56, 59]. One RCT reported an increased risk for invasive breast cancer when vitamin D supplement intakes exceeded >600 IU/day [56].

BCUK Background Briefing | Vitamin D & Breast Cancer

Three meta-analyses combining the results of multiple RCTs concluded that vitamin D supplements had no effect on reducing breast cancer risk [60–62]. A meta-analysis is statistically stronger than the analysis of any single study, due to increased numbers of participants and greater diversity among them [63].

Observational

studies Of the observational studies we considered, two studies concluded that vitamin D supplements decrease breast cancer risk [32, 33], while one found no effect [64].

One review found an inverse relationship between total vitamin D from foods and supplements and a reduced breast cancer risk [35].

In summary, most epidemiological studies do not demonstrate that taking vitamin D supplements reduces breast cancer risk.

Why aren't findings more conclusive?

Despite observational studies suggesting that a higher vitamin D status is associated with a lower incidence of breast cancer, most RCTs do not support a protective effect of vitamin D supplementation. There are several explanations for why the findings are not definitive.

One lies in study design. Observational studies can only indicate a possible association and cannot scientifically prove a causal link between vitamin D deficiency and breast cancer. Although RCTs are considered the gold standard of study designs, even these may have flaws. For example, an inadequate dose of vitamin D may have been provided or the follow-up time was too short.

Studying the role of vitamin D in the diet and its effect on breast cancer is challenging because some foods that contain vitamin D also contain calcium (e.g. milk), which helps lower breast cancer risk [65].

It is difficult to measure the amount of sunlight a person is exposed to.

There are many types of breast cancer and vitamin D may not be important for all types [66].

Breast cancer often takes more than a few years to develop, so it may be important to take vitamin D for many years (> 5) to see benefits [67].

Many factors can influence the development of breast cancer. Diet, exercise, lifestyle choices, environmental factors and genetics all play a role [68]. Numerous confounding factors must therefore be accounted for within the study design.

The serum 25(OH)D₃ level is not only dependent on vitamin D intake and production in the skin, but also on genetic factors [69].

It is still unclear what vitamin D dose (or serum 25(OH)D₃ level) is needed to potentially reduce cancer risk. One analysis of nine prospective studies suggested that circulating 25(OH)D₃ levels ranging from 67.5 to 87.5 nmol/l were associated with breast cancer risk reduction in postmenopausal women [70]. However, two RCTs provided no information on final serum 25(OH)D₃ concentrations [56, 59]. Therefore, the lack of any observed effects on breast cancer risk might be due to inadequate vitamin D supplementation.

On the other hand, if the threshold for serum 25(OH)D₃ at which supplementation might be beneficial is well below 75 nmol/L, then the participants' vitamin D status before the start of the study might be adequate and getting additional vitamin D would be of no benefit. Indeed, in three of the five RCTs we looked at, the mean baseline serum 25(OH)D₃ level was above 30 nmol/l [54, 55, 57]. Two RCTs provided no information on baseline serum 25(OH)D₃ [56, 59].

BCUK Background Briefing | Vitamin D & Breast Cancer

Conclusion

Most, but not all, epidemiological studies support an inverse association between low levels of serum vitamin D and increased breast cancer risk. Despite this finding, randomised controlled trials have not demonstrated that taking vitamin D supplements reduces breast cancer risk. Further studies are needed to clarify this finding and determine serum levels that may result in increased risk. Vitamin D deficiency is common in the UK and the global population and can lead to diseases in children and adults. Vitamin D supplements can restore serum vitamin D levels to a healthy state and are recommended for those unable to achieve sufficiency through sunshine and diet.

About Breast Cancer UK

Who are we?

Breast Cancer UK aims to prevent breast cancer through scientific research, collaboration, education and policy change. We educate and raise awareness of the risk factors for breast cancer and provide practical information to help people reduce these risks. We campaign to ensure government policies support the prevention of breast cancer. And we fund scientific research that helps to better understand what risk factors contribute to breast cancer, and how to address them

For further information on breast cancer risk factors please visit our website www.breastcanceruk.org.uk. To view this information in a more accessible format or to provide feedback, please contact us.

Disclaimer

This brief is for information purposes only and does not cover all breast cancer risks. Nor does it constitute medical advice and should not be used as an alternative to professional care. If you detect a lump or have any concerns, seek advice from your GP. Breast Cancer UK has made every effort to ensure the content of this leaflet is correct at the time of publishing but no warranty is given to that

We welcome your feedback, if you have any comments or suggestions about this brief please contact us at info@breastcanceruk.org.uk or on 0845 680 1322

effect nor any liability accepted for any loss or damage arising from its use.

Thanks to Professor Maria O'Connell and Dr Bronner Gonçalves for reviewing this document

Breast Cancer UK 2022 (all rights reserved)



BM Box 7767, London, WC1N 3XX

Email: info@breastcanceruk.org.uk

Twitter: @BreastCancer_UK

Facebook: @breastcanceruk

Instagram: @breastcanceruk

www.breastcanceruk.org.uk

Breast Cancer UK Reg. Charity no.: 1138866

Reg. Company no. 7348408

Last updated 24/4/22 (Version 1.0)

Next update 24/4/25

BCUK Background Briefing | Vitamin D & Breast Cancer

References

- 1 World Health Organization: Breast cancer, 2022. <https://www.who.int/news-room/fact-sheets/detail/breast-cancer> (accessed May 1, 2022).
- 2 Cancer Research UK: Breast cancer statistics, 2015. <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer#heading-Zero> (accessed May 1, 2022).
- 3 Breast Cancer UK: Breast Cancer Risk Factors, 2019. https://cdn.breastcanceruk.org.uk/uploads/2019/08/BCUK_Breast_cancer_risk_factors_brief_v1_12.6.2019.pdf (accessed April 17, 2022).
- 4 Garland, F. C. et al., 1990: Geographic variation in breast cancer mortality in the United States: A hypothesis involving exposure to solar radiation. *Prev Med* 1990;19:614–622. <https://pubmed.ncbi.nlm.nih.gov/2263572/>.
- 5 Harvard Health: Vitamins and Minerals, 2012. <https://www.hsph.harvard.edu/nutritionsource/vitamins/> (accessed April 19, 2022).
- 6 Nair, R. et Maseeh, A., 2012: Vitamin D: The "sunshine" vitamin. *J Pharmacol Pharmacother* 2012;3:118–126. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356951/>.
- 7 Science Direct: Secosteroids - an overview | ScienceDirect Topics, 2021. <https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/secosteroids> (accessed August 4, 2021).
- 8 National Institutes of Health: Vitamin D, 2020. <https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/> (accessed February 5, 2021).
- 9 NHS: How to get vitamin D from sunlight, NaN. <https://www.nhs.uk/live-well/healthy-body/how-to-get-vitamin-d-from-sunlight/> (accessed February 1, 2021).
- 10 Moriarty, C., 2018: Vitamin D Myths 'D'-bunked. *Yale Medicine* 2018. <https://www.yalemedicine.org/news/vitamin-d-myths-debunked>.
- 11 Haddad, J. G. et al., 1993: Human plasma transport of vitamin D after its endogenous synthesis. *J Clin Invest* 1993;91:2552–2555. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC443317/>.
- 12 Marcinowska-Suchowierska, E. et al., 2018: Vitamin D Toxicity-A Clinical Perspective. *Front Endocrinol (Lausanne)* 2018;9:550. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158375/>.
- 13 Souci-Fachmann-Kraut database: Food Composition and Nutrition Tables, 2022. <https://www.sfk.online/#/home> (accessed January 24, 2022).
- 14 Jorge, A. J. L. et al., 2018: Vitamin D Deficiency and Cardiovascular Diseases. *International Journal of Cardiovascular Sciences* 2018;31:422–432. <https://www.scielo.br/j/ijcs/a/8nGNrPGskVKNWVGJSdTbHWzb/?format=pdf&lang=en>.
- 15 Hengist, A. et al., 2019: Mobilising vitamin D from adipose tissue: The potential impact of exercise. *Nutr Bull* 2019;44:25–35. <https://onlinelibrary.wiley.com/doi/full/10.1111/nbu.12369>.
- 16 Alagarasu, K., 2021: Immunomodulatory effect of vitamin D on immune response to dengue virus infection. *Vitam Horm* 2021;117:239–252. <https://www.sciencedirect.com/science/article/abs/pii/S0083672921000455>.
- 17 Voutsadakis, I. A., 2021: Vitamin D baseline levels at diagnosis of breast cancer: A systematic review and meta-analysis. *Hematol Oncol Stem Cell Ther* 2021;14:16–26. <https://pubmed.ncbi.nlm.nih.gov/33002425/>.
- 18 Shao, T. et al., 2012: Vitamin D and breast cancer. *Oncologist* 2012;17:36–45. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267821/>.
- 19 Elmaci, I. et al., 2019: From epidemiology and neurometabolism to treatment: Vitamin D in pathogenesis of glioblastoma Multiforme (GBM) and a proposal for Vitamin D + all-trans retinoic acid + Temozolomide combination in treatment of GBM. *Metab Brain Dis* 2019;34:687–704. <https://pubmed.ncbi.nlm.nih.gov/30937698/>.
- 20 National Institutes of Health: Vitamin D, 2021. <https://ods.od.nih.gov/factsheets/VitaminD-Consumer/> (accessed February 5, 2021).

BCUK Background Briefing | Vitamin D & Breast Cancer

- 21 British Nutrition Foundation: Vitamin D and Immunity – Q & A, 2020.
<https://www.nutrition.org.uk/attachments/article/1354/Vitamin%20D%20and%20Immunity%20Q-A.pdf>
(accessed April 17, 2022).
- 22 The University of Manchester: Sunlight and vitamin D | Research Explorer | The University of Manchester, 2022.
[https://www.research.manchester.ac.uk/portal/en/projects/sunlight-and-vitamin-d\(1646e695-5cba-4ced-9ad8-cf0957aef318\).html](https://www.research.manchester.ac.uk/portal/en/projects/sunlight-and-vitamin-d(1646e695-5cba-4ced-9ad8-cf0957aef318).html)
(accessed March 11, 2022).
- 23 NHS - Royal United Hospitals Bath, 2021: PATH-023_Vitamin_D_Deficiency_in_Adults 2021.
https://www.ruh.nhs.uk/pathology/documents/clinical_guidelines/PATH-023_Vitamin_D_Deficiency_in_Adults.pdf.
- 24 British Nutrition Foundation: Key findings from NDNS report for years 9 to 11 (combined) - British Nutrition Foundation, 2020.
<https://www.nutrition.org.uk/news/2020/key-findings-from-ndns-report-for-years-9-to-11-combined/>
(accessed April 19, 2022).
- 25 NHS: Vitamin D - NHS, NaN.
<https://www.nhs.uk/conditions/vitamins-and-minerals/vitamin-d/> (accessed February 28, 2022).
- 26 Robert Koch Institut: Gesundheit A-Z - Antworten des Robert Koch-Instituts auf häufig gestellte Fragen zu Vitamin D, 2022.
https://www.rki.de/SharedDocs/FAQ/Vitamin_D/Vitamin_D_FAQ-Liste.html (accessed January 24, 2022).
- 27 Caviezel, D. et al., 2018: High Prevalence of Vitamin D Deficiency among Patients with Inflammatory Bowel Disease. *Inflamm Intest Dis* 2018;2:200–210. <https://www.karger.com/Article/Fulltext/489010>.
- 28 Bahrami, A. et al., 2018: Genetic and epigenetic factors influencing vitamin D status. *J Cell Physiol* 2018;233:4033–4043.
<https://pubmed.ncbi.nlm.nih.gov/29030989/>.
- 29 NHS: Vitamins and minerals - Vitamin D - NHS, NaN. <https://www.nhs.uk/conditions/vitamins-and-minerals/vitamin-d/> (accessed February 9, 2021).
- 30 MRC Clinical Trials Unit at UCL: What is an observational study? | MRC Clinical Trials Unit at UCL, 2021. <https://www.ctu.mrc.ac.uk/patients-public/about-clinical-trials/what-is-an-observational-study/> (accessed July 2, 2021).
- 31 Shaukat, N. et al., 2017: Association between Vitamin D deficiency and Breast Cancer. *Pak J Med Sci* 2017;33:645–649.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510119/>.
- 32 Shamsi, U. et al., 2020: A multicenter case control study of association of vitamin D with breast cancer among women in Karachi, Pakistan. *PLoS One* 2020;15:e0225402.
<https://pubmed.ncbi.nlm.nih.gov/31967989/>.
- 33 O'Brien, K. M. et al., 2017: Serum Vitamin D and Risk of Breast Cancer within Five Years. *Environ Health Perspect* 2017;125:77004.
<https://pubmed.ncbi.nlm.nih.gov/28728134/>.
- 34 Skaaby, T. et al., 2014: Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. *Cancer Epidemiol Biomarkers Prev* 2014;23:1220–1229.
<https://pubmed.ncbi.nlm.nih.gov/24789846/>.
- 35 Hossain, S. et al., 2019: Vitamin D and breast cancer: A systematic review and meta-analysis of observational studies. *Clin Nutr ESPEN* 2019;30:170–184.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570818/>.
- 36 Atoum, M. et Alzoughool F., 2017: Vitamin D and Breast Cancer: Latest Evidence and Future Steps. *Breast Cancer (Auckl)* 2017;11:1-8.
<https://journals.sagepub.com/doi/pdf/10.1177/1178223417749816>.
- 37 Estébanez, N. et al., 2018: Vitamin D exposure and Risk of Breast Cancer: a meta-analysis. *Sci Rep* 2018;8:9039.
<https://www.nature.com/articles/s41598-018-27297-1>.
- 38 McDonnell, S. L. et al., 2018: Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥ 60 vs < 20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort. *PLoS One* 2018;13:e0199265.
<https://pubmed.ncbi.nlm.nih.gov/29906273/>.
- 39 Wang, D. et al., 2013: Serum 25-hydroxyvitamin D and breast cancer risk: a meta-analysis of prospective studies. *Tumour Biol* 2013;34:3509–3517.
<https://pubmed.ncbi.nlm.nih.gov/23807676/>.

BCUK Background Briefing | Vitamin D & Breast Cancer

- 40 Kim, Y. et Je Y., 2014: Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. *Br J Cancer* 2014;110:2772–2784. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037823/>.
- 41 Sluyter, J. D. et al., 2021: Vitamin D and Clinical Cancer Outcomes: A Review of Meta-Analyses. *JBMR Plus* 2021;5:e10420.
- 42 Jiang, X. et al., 2019: Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. *Int J Epidemiol* 2019;48:1416–1424. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934026/>.
- 43 Engel, L. S. et al., 2014: Sun exposure, vitamin D receptor genetic variants, and risk of breast cancer in the Agricultural Health Study. *Environ Health Perspect* 2014;122:165–171. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915256/>.
- 44 Grant, W. B., 2002: An ecologic study of dietary and solar ultraviolet-B links to breast carcinoma mortality rates. *Cancer* 2002;94:272–281. <https://pubmed.ncbi.nlm.nih.gov/11815987/>.
- 45 Hiller, T. W. R. et al., 2020: Solar Ultraviolet Radiation and Breast Cancer Risk: A Systematic Review and Meta-Analysis. *Environ Health Perspect* 2020;128:16002. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015554/>.
- 46 Li, Y. et Ma L., 2020: Exposure to solar ultraviolet radiation and breast cancer risk: A dose-response meta-analysis. *Medicine (Baltimore)* 2020;99:e23105. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647621/>.
- 47 Pedersen, J. E. et al., 2021: Occupational exposure to solar ultraviolet B radiation and risk of subtypes of breast cancer in Danish women. *Occup Environ Med* 2021:oemed-2020-107125. <https://oem.bmj.com/content/78/4/286.long>.
- 48 National Cancer Institute: Low vitamin D linked to breast cancer metastasis, 2021. <https://www.cancer.gov/news-events/cancer-currents-blog/2016/vitamin-d-metastasis> (accessed February 1, 2021).
- 49 Welsh, J., 2004: Vitamin D and breast cancer: insights from animal models. *Am J Clin Nutr* 2004;80:1721S–4S. <https://pubmed.ncbi.nlm.nih.gov/15585794/>.
- 50 Krishnan, A. V. et Feldman D., 2011: Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. *Annu Rev Pharmacol Toxicol* 2011;51:311–336. <https://pubmed.ncbi.nlm.nih.gov/20936945/>.
- 51 Vuolo, L. et al., 2012: Vitamin D and cancer. *Front Endocrinol (Lausanne)* 2012;3:58. <https://pubmed.ncbi.nlm.nih.gov/22649423/>.
- 52 Carlberg, C. et Muñoz A., 2020: An update on vitamin D signaling and cancer. *Semin Cancer Biol* DOI: 10.1016/j.semcancer.2020.05.018.
- 53 Hariton, E. et Locascio J. J., 2018: Randomised controlled trials - the gold standard for effectiveness research: Study design: randomised controlled trials. *BJOG* 2018;125:1716. <https://pubmed.ncbi.nlm.nih.gov/29916205/>.
- 54 Manson, J. E. et al., 2019: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. *N Engl J Med* 2019;380:33–44. <https://www.nejm.org/doi/full/10.1056/nejmoa1809944>.
- 55 Crew, K. D. et al., 2019: Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). *Cancer Prev Res (Phila)* 2019;12:481–490. <https://pubmed.ncbi.nlm.nih.gov/31138522/>.
- 56 Cauley, J. A. et al., 2013: Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women's Health Initiative. *J Womens Health (Larchmt)* 2013;22:915–929. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882746/>.
- 57 Lappe, J. et al., 2017: Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial. *JAMA* 2017;317:1234–1243. <https://jamanetwork.com/journals/jama/fullarticle/2613159>.
- 58 Breast Cancer Now: DCIS (Ductal Carcinoma In Situ) Explained - Breast Cancer Care, 2015. <https://breastcancernow.org/information-support/facing-breast-cancer/diagnosed-breast->

BCUK Background Briefing | Vitamin D & Breast Cancer

- cancer/primary-breast-cancer/ductal-carcinoma-in-situ-dcis (accessed January 17, 2022).
- 59 Peila, R. et al., 2021: A Randomized Trial of Calcium Plus Vitamin D Supplementation and Risk of Ductal Carcinoma In Situ of the Breast. JNCI Cancer Spectr 2021;5:pkab072.
<https://pubmed.ncbi.nlm.nih.gov/34476342/>.
 - 60 Zhou, L. et al., 2020: The effect of vitamin D supplementation on the risk of breast cancer: a trial sequential meta-analysis. Breast Cancer Res Treat 2020;182:1–8.
<https://pubmed.ncbi.nlm.nih.gov/32405914/>.
 - 61 Sperati, F. et al., 2013: Vitamin D supplementation and breast cancer prevention: a systematic review and meta-analysis of randomized clinical trials. PLoS One 2013;8:e69269.
<https://pubmed.ncbi.nlm.nih.gov/23894438/>.
 - 62 Li, Z. et al., 2021: Effect of Vitamin D Supplementation on Risk of Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Nutr 2021;8:655727.
<https://pubmed.ncbi.nlm.nih.gov/33869269/>.
 - 63 University of Oxford - Department of Social Policy and Intervention: What is a meta-analysis?, 2022.
<https://www.spi.ox.ac.uk/what-is-a-meta-analysis> (accessed February 11, 2022).
 - 64 Abbas, S. et al., 2013: Dietary intake of vitamin D and calcium and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition. Nutr Cancer 2013;65:178–187.
<https://pubmed.ncbi.nlm.nih.gov/23441605/>.
 - 65 Lin, J. et al., 2007: Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med 2007;167:1050–1059.
<https://pubmed.ncbi.nlm.nih.gov/17533208/>.
 - 66 Yersal, O. et al., 2014: Biological subtypes of breast cancer: Prognostic and therapeutic implications. World Journal of Clinical Oncology 2014;5:412–424.
<https://www.wjgnet.com/2218-4333/full/v5/i3/412.htm>.
 - 67 Nakashima, K. et al., 2019: Does breast cancer growth rate really depend on tumor subtype? Measurement of tumor doubling time using serial ultrasonography between diagnosis and surgery. Breast Cancer 2019;26:206–214.
<https://link.springer.com/article/10.1007%2Fs12282-018-0914-0>.
 - 68 NHS: Breast cancer in women - Causes - NHS, NaN.
<https://www.nhs.uk/conditions/breast-cancer/causes/> (accessed June 11, 2021).
 - 69 Didriksen, A. et al., 2013: The serum 25-hydroxyvitamin D response to vitamin D supplementation is related to genetic factors, BMI, and baseline levels. Eur J Endocrinol 2013;169:559–567. <https://pubmed.ncbi.nlm.nih.gov/23935129/>.
 - 70 Bauer, S. R. et al., 2013: Plasma vitamin D levels, menopause, and risk of breast cancer: dose-response meta-analysis of prospective studies. Medicine (Baltimore) 2013;92:123–131.
<https://pubmed.ncbi.nlm.nih.gov/23625163/>.